Van Eck Associates Corp Gilead Sciences, Inc. Transaction History

Van Eck Associates Corp

$64.4 Billion
Q1 2024

A detailed history of Van Eck Associates Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 5,572,153 shares of GILD stock, worth $382 Million. This represents 0.63% of its overall portfolio holdings.

Number of Shares

5,572,153

Previous 4,992,415 11.61%

Holding current value

$382 Million

Previous $404 Million 0.92%

% of portfolio

0.63%

Previous 0.74%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	BUY	$71.58 - $87.29 $41.5 Million - $50.6 Million	579,738 Added 11.61%	5,572,153 $408 Million
Q4 2023 Feb 05, 2024	BUY	$73.27 - $83.09 $33.5 Million - $38 Million	457,576 Added 10.09%	4,992,415 $404 Million
Q3 2023 Nov 08, 2023	BUY	$73.94 - $80.67 $51.9 Million - $56.7 Million	702,342 Added 18.33%	4,534,839 $340 Million
Q2 2023 Aug 03, 2023	BUY	$76.01 - $86.7 $139 Million - $159 Million	1,832,292 Added 91.61%	3,832,497 $295 Million
Q1 2023 May 03, 2023	BUY	$77.31 - $88.08 $1.41 Million - $1.61 Million	18,287 Added 0.92%	2,000,205 $166 Million

Q4 2022 Feb 08, 2023	SELL	$62.32 - $89.47 $105 Million - $150 Million	-1,681,089 Reduced 45.89%	1,981,918 $170 Million
Q3 2022 Oct 27, 2022	SELL	$59.54 - $68.01 $12.3 Million - $14.1 Million	-206,643 Reduced 5.34%	3,663,007 $226 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $18 Million - $20.3 Million	311,736 Added 8.76%	3,869,650 $239 Million
Q1 2022 May 10, 2022	BUY	$57.92 - $72.58 $13.7 Million - $17.2 Million	236,611 Added 7.12%	3,557,914 $212 Million
Q4 2021 Jan 26, 2022	BUY	$64.88 - $73.64 $9.71 Million - $11 Million	149,594 Added 4.72%	3,321,303 $241 Million
Q3 2021 Nov 03, 2021	BUY	$67.69 - $73.03 $14.1 Million - $15.2 Million	208,266 Added 7.03%	3,171,709 $222 Million
Q2 2021 Aug 10, 2021	BUY	$63.47 - $69.35 $25.6 Million - $28 Million	403,756 Added 15.77%	2,963,443 $204 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $20.6 Million - $23.5 Million	342,846 Added 15.47%	2,559,687 $165 Million
Q4 2020 Feb 09, 2021	BUY	$56.65 - $64.55 $18.8 Million - $21.4 Million	332,288 Added 17.63%	2,216,841 $129 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $7.8 Million - $9.81 Million	125,630 Added 7.14%	1,884,553 $119 Million
Q2 2020 Aug 10, 2020	BUY	$72.34 - $84.0 $13.2 Million - $15.3 Million	182,106 Added 11.55%	1,758,923 $135 Million
Q1 2020 May 12, 2020	SELL	$62.63 - $80.22 $8.69 Million - $11.1 Million	-138,704 Reduced 8.09%	1,576,817 $118 Million
Q4 2019 Feb 13, 2020	BUY	$61.62 - $67.78 $18.8 Million - $20.7 Million	304,836 Added 21.61%	1,715,521 $111 Million
Q3 2019 Nov 08, 2019	BUY	$62.51 - $69.0 $616,036 - $679,995	9,855 Added 0.7%	1,410,685 $89.4 Million
Q2 2019 Aug 07, 2019	BUY	$61.87 - $69.38 $6.42 Million - $7.2 Million	103,768 Added 8.0%	1,400,830 $94.6 Million
Q1 2019 May 13, 2019	BUY	$62.53 - $70.05 $13.7 Million - $15.3 Million	218,854 Added 20.3%	1,297,062 $84.3 Million
Q4 2018 Feb 12, 2019	BUY	$60.54 - $79.0 $3.08 Million - $4.02 Million	50,893 Added 4.95%	1,078,208 $67.4 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $15.5 Million - $17.2 Million	217,516 Added 26.86%	1,027,315 $79.3 Million
Q2 2018 Aug 13, 2018	SELL	$64.88 - $75.68 $1.89 Million - $2.21 Million	-29,167 Reduced 3.48%	809,799 $57.4 Million
Q1 2018 May 11, 2018	SELL	$72.84 - $88.8 $17.6 Million - $21.4 Million	-241,163 Reduced 22.33%	838,966 $63.3 Million
Q4 2017 Feb 12, 2018	BUY	$71.15 - $83.52 $1.02 Million - $1.2 Million	14,399 Added 1.35%	1,080,129 $77.4 Million
Q3 2017 Nov 09, 2017	SELL	$72.11 - $85.47 $25.8 Million - $30.6 Million	-358,011 Reduced 25.15%	1,065,730 $86.3 Million
Q2 2017 Aug 11, 2017	BUY	N/A	1,423,741	1,423,741 $101 Million

Others Institutions Holding GILD

# of Institutions

1,884

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $86B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Gilead Sciences, Inc. Transaction History